Manning-Geist, B.L.; Gnjatic, S.; Aghajanian, C.; Konner, J.; Kim, S.H.; Sarasohn, D.; Soldan, K.; Tew, W.P.; Sarlis, N.J.; Zamarin, D.;
et al. Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. Cancers 2023, 15, 1458.
https://doi.org/10.3390/cancers15051458
AMA Style
Manning-Geist BL, Gnjatic S, Aghajanian C, Konner J, Kim SH, Sarasohn D, Soldan K, Tew WP, Sarlis NJ, Zamarin D,
et al. Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. Cancers. 2023; 15(5):1458.
https://doi.org/10.3390/cancers15051458
Chicago/Turabian Style
Manning-Geist, Beryl L., Sacha Gnjatic, Carol Aghajanian, Jason Konner, Sarah H. Kim, Debra Sarasohn, Krysten Soldan, William P. Tew, Nicholas J. Sarlis, Dmitriy Zamarin,
and et al. 2023. "Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission" Cancers 15, no. 5: 1458.
https://doi.org/10.3390/cancers15051458
APA Style
Manning-Geist, B. L., Gnjatic, S., Aghajanian, C., Konner, J., Kim, S. H., Sarasohn, D., Soldan, K., Tew, W. P., Sarlis, N. J., Zamarin, D., Kravetz, S., Laface, I., Rasalan-Ho, T., Qi, J., Wong, P., Sabbatini, P. J., & O’Cearbhaill, R. E.
(2023). Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. Cancers, 15(5), 1458.
https://doi.org/10.3390/cancers15051458
